Back to top
more

Fulcrum Therapeutics (FULC)

(Delayed Data from NSDQ)

$3.26 USD

3.26
843,623

+0.05 (1.56%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $3.26 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid

by Zacks Equity Research

Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

by Zacks Equity Research

Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.

Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook

by Zacks Equity Research

Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

by Zacks Equity Research

Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.

Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.

SpringWorks (SWTX) Q2 Earnings Beat, Ogsiveo Drives Revenues

by Zacks Equity Research

SpringWorks (SWTX) reports better-than-expected second-quarter results. The newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

by Zacks Equity Research

Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.

Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss

by Zacks Equity Research

Beam Therapeutics (BEAM) reports mixed second-quarter results. The company remains focused on pipeline development.

Fulcrum Therapeutics (FULC) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Fulcrum Therapeutics (FULC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know

by Zacks Equity Research

Does Fulcrum Therapeutics, Inc. (FULC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Fulcrum Therapeutics (FULC) Have the Potential to Rally 68.69% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 68.7% in Fulcrum Therapeutics (FULC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

New Strong Buy Stocks for August 5th

by Zacks Equity Research

KGC, MCY, WGS, CHRW and FULC have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2023.

The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers

by Zacks Equity Research

Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.

Ekta Bagri headshot

Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

by Ekta Bagri

Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.

Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 69.2% upside potential for Fulcrum Therapeutics (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of 0% and 16.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 12.17% and 53.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 9.09% and 34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics

by Zacks Equity Research

Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More

by Zacks Equity Research

Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.

Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate

by Zacks Equity Research

Fulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its pipeline candidate FTX-6058, to treat patients with sickle cell disease.

Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 13.64% and 45.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 12.77% and 82.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Equillium, Inc. (EQ) delivered earnings and revenue surprises of 45% and 21.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?